Iñiguez C, Larrodé P, Mayordomo J I, González P, Adelantado S, Yubero A, Trés A, Morales F
Department of Neurology, Hospital Clínico Universitario, Zaragoza, Spain.
Neurology. 1998 Sep;51(3):868-70. doi: 10.1212/wnl.51.3.868.
Peripheral neuropathy (PN) is the main side effect with cycles of paclitaxel at standard doses (175 mg/m2 for 21 days). Administration of a single high-dose paclitaxel (HDP) is a novel approach for the treatment of cancer. We have prospectively measured neurotoxicity induced by HDP during a phase I trial. Nineteen patients were treated with escalating doses of paclitaxel by 24-hour infusion. In our study, PN induced by HDP was moderate, reversible, and not dose limiting. Severe PN was seen in patients who had received previous neurotoxic chemotherapy, and caution on the administration of HDP in this setting is warranted.
周围神经病变（PN）是标准剂量（175mg/m²，持续21天）紫杉醇治疗周期的主要副作用。单次大剂量紫杉醇（HDP）给药是一种治疗癌症的新方法。我们在一项I期试验中前瞻性地测量了HDP诱导的神经毒性。19名患者通过24小时输注接受递增剂量的紫杉醇治疗。在我们的研究中，HDP诱导的PN为中度、可逆且非剂量限制性的。在接受过先前神经毒性化疗的患者中观察到严重PN，因此在这种情况下给予HDP时应谨慎。
